ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 306 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.19 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,418,464 | -73.8% | 238,871 | -65.2% | 0.00% | -75.0% |
| Q2 2023 | $24,463,902 | +1.6% | 686,032 | -27.6% | 0.00% | -20.0% |
| Q1 2023 | $24,081,867 | -28.9% | 948,105 | +13.5% | 0.01% | -37.5% |
| Q4 2022 | $33,886,785 | +29.9% | 835,473 | +5.8% | 0.01% | +33.3% |
| Q3 2022 | $26,088,000 | +27.4% | 789,348 | +35.7% | 0.01% | +20.0% |
| Q2 2022 | $20,482,000 | -3.2% | 581,697 | +26.4% | 0.01% | 0.0% |
| Q1 2022 | $21,165,000 | -25.4% | 460,224 | +7.6% | 0.01% | -16.7% |
| Q4 2021 | $28,369,000 | +0.1% | 427,895 | -5.7% | 0.01% | 0.0% |
| Q3 2021 | $28,328,000 | -39.1% | 453,763 | -19.2% | 0.01% | -40.0% |
| Q2 2021 | $46,535,000 | +4.6% | 561,888 | -16.3% | 0.01% | -16.7% |
| Q1 2021 | $44,492,000 | -11.0% | 670,963 | +3.0% | 0.01% | -7.7% |
| Q4 2020 | $49,980,000 | +83.8% | 651,372 | +3.1% | 0.01% | +85.7% |
| Q3 2020 | $27,196,000 | +27.4% | 631,582 | +27.8% | 0.01% | -12.5% |
| Q2 2020 | $21,346,000 | +58.3% | 494,230 | +5.4% | 0.01% | +33.3% |
| Q1 2020 | $13,484,000 | -56.7% | 468,702 | -4.6% | 0.01% | -53.8% |
| Q4 2019 | $31,170,000 | +301.2% | 491,407 | +78.2% | 0.01% | +225.0% |
| Q3 2019 | $7,769,000 | +71.0% | 275,694 | +60.8% | 0.00% | +100.0% |
| Q2 2019 | $4,543,000 | +49.4% | 171,438 | +3.5% | 0.00% | 0.0% |
| Q1 2019 | $3,040,000 | -5.4% | 165,633 | -36.0% | 0.00% | 0.0% |
| Q4 2018 | $3,213,000 | -44.6% | 258,613 | -14.6% | 0.00% | -33.3% |
| Q3 2018 | $5,802,000 | -41.0% | 302,712 | -58.1% | 0.00% | -25.0% |
| Q2 2018 | $9,837,000 | +1451.6% | 723,294 | +722.5% | 0.00% | – |
| Q1 2018 | $634,000 | +60.1% | 87,939 | -18.2% | 0.00% | – |
| Q4 2017 | $396,000 | +39.9% | 107,509 | +64.3% | 0.00% | – |
| Q3 2017 | $283,000 | +515.2% | 65,452 | +129.7% | 0.00% | – |
| Q2 2017 | $46,000 | +53.3% | 28,500 | +77.0% | 0.00% | – |
| Q1 2017 | $30,000 | -61.0% | 16,100 | -67.9% | 0.00% | – |
| Q4 2016 | $77,000 | -77.9% | 50,100 | +5.7% | 0.00% | – |
| Q3 2016 | $348,000 | +346.2% | 47,400 | +221.6% | 0.00% | – |
| Q2 2016 | $78,000 | – | 14,739 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |